目的探讨选择性抗凝血酶制剂-阿加曲班对急性早幼粒细胞白血病(APL)合并弥散性血管内凝血(DIC)在诱导缓解治疗期间出血情况的控制,疗效和安全价值。方法(1)将确诊为 APL 合并 DIC 患者30例,随机分为2组,1组为低分子肝素治疗组(简称 LMWH 组),1组为阿加曲班治疗组(简称阿加曲班组)。2组(APL 合并 DIC)患者均给予常规诱导缓解治疗(简称常规治疗),0.1%三氧化二砷 Objective To investigate the control, efficacy and safety of selective antithrombin-argatroban on the hemorrhage of acute promyelocytic leukemia (APL) and disseminated intravascular coagulation (DIC) during induction remission. Methods (1) Thirty patients diagnosed as APL complicated with DIC were randomly divided into two groups, one was treated with low molecular weight heparin (LMWH), one was treated with argatroban (argatroban) . Patients in both groups (APL combined with DIC) were given conventional induction therapy (abbreviated as routine treatment), 0.1% arsenic trioxide